Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Batist

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
Investigational New Drugs|March 4, 2005
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupG Goss, H Hirte, W H Miller, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
A network approach to developing immuno-oncology combinations in CanadaV Higenell, R Fajzel, G Batist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialJ Rodon, J C Soria, R Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
Investigational New Drugs|March 4, 2005
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupG Goss, H Hirte, W H Miller, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
A network approach to developing immuno-oncology combinations in CanadaV Higenell, R Fajzel, G Batist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialJ Rodon, J C Soria, R Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Pageof 12